Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.66 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.64 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.56 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.52 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.50 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.50 |
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4835879 | 0.86 | LOXL2 (0.60) | LOXL2CYP4F2CYP4A11ALDH1A1KDM4E | |
| SCHEMBL10106423 | 0.85 | LOXL2 (0.64) | LOXL2CYP4F2CYP4A11ALDH1A1KDM4E | |
| SCHEMBL27989651 | 0.85 | LOXL2 (0.47) | LOXL2CYP4F2CYP4A11ALDH1A1KDM4E | |
| SCHEMBL16706893 | 0.84 | LOXL2 (0.62) | LOXL2CYP4F2CYP4A11ALDH1A1KDM4E | |
| SCHEMBL16844982 | 0.84 | MEP1B (0.65) | CYP4F2CYP4A11ALDH1A1KDM4EMAPT | |
| SCHEMBL24219815 | 0.83 | MEP1B (0.51) | LOXL2CYP4F2CYP4A11ALDH1A1KDM4E | |
| SCHEMBL1318407 | 0.83 | HSD17B2 (0.54) | CYP4F2CYP4A11ALDH1A1KDM4EMAPT | |
| SCHEMBL29592260 | 0.83 | LOXL2 (0.70) | LOXL2CYP4F2CYP4A11ALDH1A1KDM4E | |
| SCHEMBL28212 | 0.83 | LOXL2 (0.70) | LOXL2CYP4F2CYP4A11ALDH1A1KDM4E | |
| SCHEMBL29137828 | 0.83 | SLC7A5 (0.59) | LOXL2CYP4F2CYP4A11ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230132298-A1 | OXABOROLE ESTERS AND USES THEREOF | ANACOR PHARMACEUTICALS, LLC | 2023-04-27 | — | — | US | disclosed |
| EP-3578562-B1 | L-VALINATE AMIDE BENZOXABOROLE DERIVATIVES FOR THE TREATMENT OF PARASITIC DISEASES | ANACOR PHARMACEUTICALS INC (US) | 2021-06-23 | — | — | EP | disclosed |
| US-10882872-B2 | Oxaborole esters and uses thereof | ANACOR PHARMACEUTICALS, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| EP-3578562-A1 | L-VALINATE AMIDE BENZOXABOROLE DERIVATIVES FOR THE TREATMENT OF PARASITIC DISEASES | Anacor Pharmaceuticals, Inc (US) | 2019-12-11 | — | — | EP | disclosed |
| WO-2017195069-A1 | OXABOROLE ESTERS AND USES THEREOF | ANACOR PHARMACEUTICALS, INC. (US) | 2017-11-16 | — | — | WO | disclosed |
| US-20170327519-A1 | OXABOROLE ESTERS AND USES THEREOF | ANACOR PHARMACEUTICALS, INC. (US) | 2017-11-16 | — | — | US | disclosed |
| US-8962667-B2 | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases | Microdose Therapeutix, Inc. (US) | 2015-02-24 | — | — | US | disclosed |
| US-8962667-B2 | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases | Microdose Therapeutix, Inc. (US) | 2015-02-24 | — | — | US | disclosed |
| CN-102985417-B | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors | INCYTE CORP | 2015-01-28 | — | — | CN | disclosed |
| US-20140363395-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES | MICRODOSE THERAPEUTX INC (US) | 2014-12-11 | — | — | US | disclosed |
| WO-2012027965-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-03-08 | — | — | WO | disclosed |
| EP-1342719-B1 | Benzodiazepine derivatives useful as CCK-Receptor Antagonists | FERRING BV (NL) | 2011-04-13 | — | — | EP | disclosed |
| EP-1070708-B1 | Triazole derivatives | HOFFMANN LA ROCHE (CH) | 2004-01-14 | — | — | EP | disclosed |
| EP-1342719-A1 | Benzodiazepine derivatives useful as CCK-Receptor Antagonists | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2003-09-10 | — | — | EP | disclosed |
| US-6265426-B1 | CENTRAL NERVOUS SYSTEM DISORDERS | HOFFMANN-LA ROCHE INC. | 2001-07-24 | — | — | US | disclosed |
| EP-1070708-A1 | Triazole and imidazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2001-01-24 | — | — | EP | disclosed |
| US-5962451-A | GASTROINTESTINAL DISORDERS; ANTIULCER AGENT; ANTICANCER AGENTS; SIDE-EFFECT REDUCTION | FERRING BV (NL) | 1999-10-05 | — | — | US | disclosed |
| US-5688943-A | CHOLECYSTOKININ ANTAGONIST; ANTIULCER AGENTS; PSYCHOLOGICAL DRUGS; ANXIOLYTIC AGENTS; CONTROLLING APPETITE | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1997-11-18 | — | — | US | disclosed |
| EP-0628033-A1 | BENZODIAZEPIN DERIVATIVES USEFUL AS CCK-RECEPTOR ANTAGONISTS | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1994-12-14 | — | — | EP | disclosed |
| WO-1993016999-A1 | BENZODIAZEPIN DERIVATIVES USEFUL AS CCK-RECEPTOR ANTAGONISTS | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1993-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230132298-A1 | OXABOROLE ESTERS AND USES THEREOF | OXA1L, HSD17B12, OXER1 | LOXL2 120/4885CYP4F2 230/4885CYP4A11 223/4885 |
| US-10882872-B2 | Oxaborole esters and uses thereof | OXA1L, HSD17B12, OXER1 | LOXL2 120/4885CYP4F2 230/4885CYP4A11 223/4885 |
| US-20140363395-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES | TTPA, HAVCR2, ZC3HAV1 | LOXL2 2970/4885CYP4F2 1284/4885CYP4A11 707/4885 |
| US-20170327519-A1 | OXABOROLE ESTERS AND USES THEREOF | OXA1L, HSD17B12, OXER1 | LOXL2 120/4885CYP4F2 230/4885CYP4A11 223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.